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Reply to Torre and Pugliese
Sir—The letter by Torre and Pugliese [1]
questions whether all patients with pul-
monary hypertension related to HIV
(PAHRH) should be treated with HAART,
as we suggested on the basis of the results
of our recent study [2]. Because PAHRH
is a serious complication that, if untreated,
has a high mortality rate, treatments that
are targeted to reduce mortality are clearly
indicated. In the era of HAART, pulmo-
nary hypertension and its progression,
more than the HIV infection itself, will
determine the patient’s prognosis. How-
ever, in the pre-HAART era, approxi-
mately half of all patients with PAHRH
died of HIV-related causes [3]. Treatment
with intravenous epoprostenol, inhaled il-
oprost, and, more recently, oral bosentan
have been shown to significantly decrease
the right ventricular systolic pressure over
right atrial pressure gradient in patients
with PAHRH. Although not always
proven, because of the lack of a control
group, the magnitude of the decrease in
pressure gradient achieved with these
drugs is likely to have a positive impact
on overall survival rates.
To our knowledge, our study [2] is the
only one that has systematically evaluated
the time course of the pressure gradient
as a function of antiretroviral therapy in
a larger patient population. In the study
by Pugliese et al. [4], a difference in
PAHRH frequency from 0.7% to 2.0% was
reported between patients treated with 1
or 2 nucleoside analogues and patients
treated with HAART during a later time
period. Because the authors do not report
the overall number of HIV-infected pa-
tients in their cohort, a calculation of in-
cidence is not possible, and the data can-
not be interpreted as showing an increase
in PAHRH frequency due to HAART. The
unusually high frequency of 2.0% suggests
that a bias has affected the data; possibly
there were more patients with PAHRH re-
ceiving HAART than patients not receiv-
ing antiretroviral therapy. More impor-
tantly, neither the definition of pulmonary
hypertension nor the pressure gradient
values nor their time course are men-
tioned in the article [4].
Current treatment recommendations
for HAART only consider whether the
CD4 cell count is 1350 cells/mm3 if a pa-
tient is asymptomatic. However, we con-
sider PAHRH to be a symptom of HIV
infection, because it is epidemiologically
linked to HIV infection, and, possibly, is
associated with human herpesvirus 8 coin-
fection; pathological immune activation
due to HIV; genetic factors; or other, yet
unknown, factors. Although we agree that
starting HAART at a CD4 cell count of
1350 cells/mm3 is not warranted for the
broad population of asymptomatic pa-
tients, HAART does lead to a decrease in
immune activation, irrespective of the
CD4 cell count. This effect may have in-
directly contributed to the improved he-
modynamics seen in our study. In the face
of the rare occurrence—but high mortal-
ity—of PAHRH, we believe that every step
should be taken to improve the prognosis
of patients with PAHRH. On the basis of
our data, we believe that HAART should
always be initiated, because it stabilizes or
decreases the pulmonary hypertension
and prolongs survival [2]. Additional
treatments that improve the hemody-
namics should be started if a patient is
moderately to severely symptomatic.
Among patients who are moderately
symptomatic, the endothelin receptor an-
tagonist bosentan seems to be the drug of
choice, because of the availability of the
drug in an oral formulation and because
of its proven efficacy [5].
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